These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 31079535)

  • 21. Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial.
    Botson JK; Obermeyer K; LaMoreaux B; Zhao L; Weinblatt ME; Peterson J
    Arthritis Res Ther; 2022 Dec; 24(1):281. PubMed ID: 36575505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout.
    Lipsky PE; Calabrese LH; Kavanaugh A; Sundy JS; Wright D; Wolfson M; Becker MA
    Arthritis Res Ther; 2014 Mar; 16(2):R60. PubMed ID: 24588936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement in hepatic fibrosis estimated by Fibrosis-4 index in pegloticase treated chronic refractory gout patients.
    Schlesinger N; Rustgi VK; Yeo AE; Lipsky PE
    Clin Exp Rheumatol; 2023 Jan; 41(1):60-66. PubMed ID: 35349415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interventions for tophi in gout.
    Sriranganathan MK; Vinik O; Bombardier C; Edwards CJ
    Cochrane Database Syst Rev; 2014 Oct; (10):CD010069. PubMed ID: 25330136
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monosodium urate crystal depletion and bone erosion remodeling during pegloticase treatment in patients with uncontrolled gout: Exploratory dual-energy computed tomography findings from MIRROR RCT.
    Dalbeth N; Botson J; Saag K; Kumar A; Padnick-Silver L; LaMoreaux B; Becce F
    Joint Bone Spine; 2024 Jul; 91(4):105715. PubMed ID: 38447697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout.
    Calabrese LH; Kavanaugh A; Yeo AE; Lipsky PE
    Arthritis Res Ther; 2017 Aug; 19(1):191. PubMed ID: 28818095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings.
    Botson JK; Saag K; Peterson J; Parikh N; Ong S; La D; LoCicero K; Obermeyer K; Xin Y; Chamberlain J; LaMoreaux B; Verma S; Sainati S; Grewal S; Majjhoo A; Tesser JRP; Weinblatt ME
    Arthritis Rheumatol; 2023 Feb; 75(2):293-304. PubMed ID: 36099211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout.
    Yue CS; Huang W; Alton M; Maroli AN; Waltrip RW; Wright D; Marco MD
    J Clin Pharmacol; 2008 Jun; 48(6):708-18. PubMed ID: 18420531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pegloticase failure and a possible solution: Immunosuppression to prevent intolerance and inefficacy in patients with gout.
    Berhanu AA; Krasnokutsky S; Keenan RT; Pillinger MH
    Semin Arthritis Rheum; 2017 Jun; 46(6):754-758. PubMed ID: 27769591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recapture and improved outcome of pegloticase response with methotrexate-A report of two cases and review of the literature.
    Bessen SY; Bessen MY; Yung CM
    Semin Arthritis Rheum; 2019 Aug; 49(1):56-61. PubMed ID: 30583886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
    Khanna PP; Khanna D; Cutter G; Foster J; Melnick J; Jaafar S; Biggers S; Rahman AKMF; Kuo HC; Feese M; Kivitz A; King C; Shergy W; Kent J; Peloso PM; Danila MI; Saag KG
    Arthritis Rheumatol; 2021 Aug; 73(8):1523-1532. PubMed ID: 33750034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout.
    Baraf HSB; Khanna PP; Kivitz AJ; Strand V; Choi HK; Terkeltaub R; Dalbeth N; DeHaan W; Azeem R; Traber PG; Keenan RT
    Rheumatology (Oxford); 2024 Apr; 63(4):1058-1067. PubMed ID: 37449908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study.
    Botson JK; Tesser JRP; Bennett R; Kenney HM; Peloso PM; Obermeyer K; Song Y; LaMoreaux B; Zhao L; Xin Y; Chamberlain J; Ramanathan S; Weinblatt ME; Peterson J
    Arthritis Res Ther; 2022 Aug; 24(1):208. PubMed ID: 36008814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intensive urate-lowering with pegloticase plus methotrexate co-therapy in uncontrolled gout patients with and without chronic kidney disease: A retrospective case series.
    Albert J; Broadwell A; Padnick-Silver L; Marder B; LaMoreaux B
    Medicine (Baltimore); 2024 Mar; 103(10):e37424. PubMed ID: 38457582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation and treatment of gout as a chronic disease.
    Perez-Ruiz F; Herrero-Beites AM
    Adv Ther; 2012 Nov; 29(11):935-46. PubMed ID: 23104464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients.
    Hershfield MS; Ganson NJ; Kelly SJ; Scarlett EL; Jaggers DA; Sundy JS
    Arthritis Res Ther; 2014 Mar; 16(2):R63. PubMed ID: 24602182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout.
    Biggers K; Scheinfeld N
    Curr Opin Investig Drugs; 2008 Apr; 9(4):422-9. PubMed ID: 18393109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Gout: an overview of available urate lowering therapies].
    Richette P
    Ann Pharm Fr; 2012 May; 70(3):133-8. PubMed ID: 22655581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pegloticase and lowering blood pressure in refractory gout; is it uric acid or hydrogen peroxide?
    Fini MA; Stenmark KR
    Eur J Intern Med; 2019 Nov; 69():e11-e12. PubMed ID: 31471165
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacokinetics and pharmacodynamics of pegloticase in patients with end-stage renal failure receiving hemodialysis.
    Bleyer AJ; Wright D; Alcorn H
    Clin Nephrol; 2015 May; 83(5):286-92. PubMed ID: 25816806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.